28 related articles for article (PubMed ID: 273888)
1. Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors.
Focan C; Olivier R; Le Hung S; Bays R; Claessens JJ; Debruyne H
Cancer Chemother Pharmacol; 1981; 6(2):175-81. PubMed ID: 7307235
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapists' need for uniform and rational nomenclature and classification of common lymphosarcomas and reticulosarcoma (hematosarcomas or non-Hodgkin's lymphomas).
Mathé G
Cancer Chemother Pharmacol; 1978; 1(4):183-6. PubMed ID: 373918
[No Abstract] [Full Text] [Related]
3. Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.
Mathé G; Misset JL; De Vassal F; Gouveia J; Hayat M; Machover D; Belpomme D; Pico JL; Schwarzenberg L; Ribaud P; Musset M; Jasmin C; De Luca L
Cancer Treat Rep; 1978 May; 62(5):805-9. PubMed ID: 274996
[TBL] [Abstract][Full Text] [Related]
4. [Continuous 5-day vindesine in the treatment of leukemias and lymphomas (author's transl)].
Maraninchi D; Gastaut JA; Tubiana N; Carcassonne Y
Bull Cancer; 1981; 68(4):338-42. PubMed ID: 6947833
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of vindesine in patients with acute leukemia.
Sklaroff RB; Arlin Z; Young CW
Cancer Treat Rep; 1979; 63(11-12):2063-5. PubMed ID: 294307
[TBL] [Abstract][Full Text] [Related]
6. Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.
Bayssas M; Gouveia J; Ribaud P; Musset M; de Vassal F; Pico JL; de Luca L; Misset JL; Machover D; Belpomme D; Schwarzenberg L; Jasmin C; Hayat M; Mathé G
Cancer Chemother Pharmacol; 1979; 2(4):247-55. PubMed ID: 287569
[TBL] [Abstract][Full Text] [Related]
7. [Phase II study of vindesine in hematological malignancies].
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2509-15. PubMed ID: 6580841
[TBL] [Abstract][Full Text] [Related]
8. [Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)].
Marthé G; Misset JL; de Vassal F; Hayat M; Gouveia J; Machover D; Belpomme D; Schwarzenberg L; Ribaud P; Pico JL; Musset M; Jasmin C; de Luca L
Nouv Presse Med; 1978 Feb; 7(7):525-8. PubMed ID: 273888
[TBL] [Abstract][Full Text] [Related]
9. The use of drugs in combination for the treatment of cancer: rationale and results.
DeVita VT; Schein PS
N Engl J Med; 1973 May; 288(19):998-1006. PubMed ID: 4348752
[No Abstract] [Full Text] [Related]
10. Vindesine: a new vinca alkaloid.
Bayssas M; Gouveia J; de Vassal F; Misset JL; Schwarzenberg L; Ribaud P; Musset M; Jasmin C; Hayat M; Mathé G
Recent Results Cancer Res; 1980; 74():91-7. PubMed ID: 7003662
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid.
Cersosimo RJ; Bromer R; Licciardello JT; Hong WK
Pharmacotherapy; 1983; 3(5):259-74. PubMed ID: 6359081
[TBL] [Abstract][Full Text] [Related]
12. Vindesine in the treatment of leukaemia.
Gökbuget N; Hoelzer D
Leuk Lymphoma; 1997 Aug; 26(5-6):497-506. PubMed ID: 9389357
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
